Past Studies

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X |Y | Z


Below, you can find information on past studies that are closed or are in wrap-up.

  

CIRT
Title: A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Primary Objective: The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages.
Sponsor: Brigham and Women's Hospital in collaboration with the National Heart, Lung, and Blood Institute 
Primary Investigator:  Daniel Anderson, MD, PhD
Clinical Trials Website: NCT01594333 

 

GLORIA-AF
Title: GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)
Primary Objective: In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
Sponsor: Boehringer Ingelheim
Primary Investigator:  Daniel Anderson, MD, PhD
Clinical Trials Website: NCT01468701

top

GREAT
Title: 'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation
Primary Objective: This is a prospective observational cohort Registry designed to obtain data on device performance and clinical outcomes of patients treated with Gore Endovascular Aortic products.
Sponsor: W.L.Gore & Associates
Primary Investigator:  Daniel Anderson, MD, PhD
Clinical Trials Website: NCT01658787

top

MOMENTUM IDE
Title: Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol
Primary Objective: The objective of the study is to evaluate the safety and effectiveness of the HM3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
Sponsor: Thoratec Corporation
Primary Investigator:  John Um, MD
Clinical Trials Website: NCT02224755

top

N-TA^3CT
Title: Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)
Primary Objective: The primary aim of this study is to determine if doxycycline (100 mg bid) will inhibit (by at least 40%) the increase in greatest transverse diameter of small abdominal aortic aneurysms (3.5-5.0 cm in men, 3.5-4.5 cm in women) over a 24-month period of observation in comparison to a placebo-treated control group.
Sponsor: University of Maryland in collaboration with the National Institute on Aging (NIA)
Primary Investigator: Jason Mactaggart, MD
Clinical Trials Website: NCT01756833

top

PIONEER
Title: A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).
Primary Objective: The purpose of this study is to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
Sponsor: Novartis Pharmaceuticals
Primary Investigator: Ronald Zolty, MD, PhD
Clinical Trials Website:NCT02554890

top

RESTAGE-HF
Title: Remission From Stage D Heart Failure (RESTAGE-HF)
Primary Objective: The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months.
Sponsor: University of Louisville in collaboration with Thoratec Corporation
Primary Investigator:  Brian Lowes, MD, PhD
Clinical Trials Website: NCT01774656

top

UNTOUCHED
Title: Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction
Primary Objective: This study assesses the 18-month incidence of inappropriate shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death.
Sponsor: Boston Scientific Corporation
Primary Investigator:  Shane Tsai, MD
Clinical Trials Website: NCT02433379

top

WRAP-IT
Title: Cardiovascular Implantable Electronic Device (CIED) Antibiotic Envelope Infection Prevention Trial
Primary Objective: This study will evaluate the ability of the TYRX envelope to reduce major CIED infections through 12-months post-procedure following CIED generator replacement, upgrade, revision, or de novo CRT-D implant.
Sponsor: Medtronic Cardiac Rhythm and Heart Failure
Primary Investigator:  Daniel Anderson, MD, PhD
Clinical Trials Website: NCT02277990

top